• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 5 is a forest plot (i.e., a graph that depicts a meta-analysis plot) showing the individual and pooled relative risks and 95% confidence intervals (random effects model) from 2 trials for the comparison of dual therapy with pegylated interferon plus ribavirin for 48 versus 24 weeks in patients with genotype 2 or 3 infection on sustained virological response. In the center of the graph is a solid vertical line corresponding to no effect. The individual studies are depicted at varying distances along this line as horizontal lines with a solid square in the middle. The size of the square varies in relation to the size of the study and the weight of the individual study in the overall analysis. The pooled effect is represented by a diamond at the bottom of the graph. The two trials found no difference between 48 versus 24 weeks of dual therapy in the likelihood of achieving an SVR, the pooled relative risk was 0.97, with a 95% confidence interval of 0.84 to 1.11; I-squared = 32.1%, p = 0.186.

Figure 5Sustained virologic response: Dual therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirin for 48 versus 24 weeks in patients with genotype 2 or 3 infection

From: Results

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.